PDF(Pubmed)
Abstract：
Although not registered for feline infectious peritonitis (FIP) in Japan, nucleoside analogs have shown efficacy and we have been offering them to owners of cats with FIP at our clinic since January 2020. The aim of this study was to investigate outcomes in cats with FIP who received GS-441524 or molnupiravir. Diagnosis of FIP was based on clinical signs, laboratory test results, and the presence of feline coronavirus RNA in blood or effusion aspirate. After providing verbal and written information, owners of cats with a presumptive diagnosis of FIP with a were offered antiviral treatment with commercially sourced GS-441524 from June 2020, and either GS-441524 or compounded molnupiravir from January 2022. Dosing was 12.5-25 mg/kg/day for GS-441524 and 20-40 mg/kg/day for molnupiravir, depending on the presence of effusion and neurological and/or ocular signs, and continued for 84 days. Overall, 118 cats with FIP (effusive in 76) received treatment, 59 with GS-4421524 and 59 with molnupiravir. Twenty cats died, 12/59 (20.3%) in the GS-441524 group and 8/59 (13.6%) in the molnupiravir group (p = 0.326), with most deaths within the first 10 days of starting treatment. Among survivors, neurological and ocular signs resolved in all but one cat, who had persistent seizures. Of the cats completing treatment, 48/48 in the GS-441524 group and 51/52 in the molnupiravir group achieved remission. Laboratory parameters normalized within 6 to 7 weeks of starting drug administration. Adverse events, such as primarily hepatic function abnormalities, were transient and resolved without specific intervention. Our data indicate that GS-441524 and molnupiravir show similar effects and safety in cats with FIP.
摘要：
虽然没有在日本注册猫传染性腹膜炎（FIP），核苷类似物已显示出疗效，自2020年1月以来，我们一直在我们的诊所为FIP猫的主人提供它们。这项研究的目的是调查接受GS-441524或molnupiravir的FIP猫的结果。FIP的诊断是基于临床体征，实验室测试结果，血液或积液中存在猫冠状病毒RNA。在提供口头和书面信息后，自2020年6月起,为FIP推定诊断为a的猫的主人提供了商业来源的GS-441524的抗病毒治疗,自2022年1月起,向其提供了GS-441524或复合莫诺比拉韦的抗病毒治疗.GS-441524的剂量为12.5-25毫克/千克/天，莫那普拉韦的剂量为20-40毫克/千克/天，根据积液和神经和/或眼部体征的存在，持续了84天。总的来说,118只FIP猫（76只）接受了治疗，59与GS-4421524和59与molnupiravir。二十只猫死了，GS-441524组中的12/59（20.3％）和molnupiravir组中的8/59（13.6％）（p=0.326），在开始治疗的前10天内死亡最多。在幸存者中，除了一只猫，所有的神经和眼部症状都得到了解决，谁有持续的癫痫发作。在完成治疗的猫中，GS-441524组48/48和molnupiravir组51/52获得缓解。实验室参数在开始药物施用的6至7周内标准化。不良事件,如主要肝功能异常，是短暂的，没有具体干预就解决了。我们的数据表明，GS-441524和molnupiravir在FIP猫中显示出相似的效果和安全性。
